Zivo Bioscience
ZIVO · OTC
About ZIVO
- Employees
- 7
- Headquarters
- Troy, Michigan
- Listed
- Oct 6, 2000
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Website
- zivobioscience.com
ZIVO key statistics
- Market cap
- 16.61M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 867
- Volume
- 1.05K
- Open price
- $6.50
- High today
- $6.80
- Low today
- $6.50
- 52 Week high
- $17.50
- 52 Week low
- $1.11
Zivo Bioscience (ZIVO) at a glance
As of Oct 19, 2026, Zivo Bioscience (ZIVO) shares are priced at $6.80, giving the company a market cap of 16.61M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $6.50 and $6.80. The current price is 4.6% above the day's low and 0.0% below its high.
Volume so far is 1.05K shares, above the average of 867 shares a day.
Over the past year Zivo Bioscience has ranged from $1.11 to $17.50, and now sits 35% of the way up that range.
Zivo Bioscience met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY25 it reported -$0.43 per share against an estimate of -$0.4182.
ZIVO earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 3 of the last 8 quarters, by 31.2% on average.
- Q1 FY23: reported -$1.26 per share against an estimate of -$1.47
- Q2 FY23: reported -$1.32 per share against an estimate of -$1.22
- Q1 FY24: reported -$0.47 per share against an estimate of -$0.816
- Q2 FY24: reported -$2.78 per share against an estimate of -$0.4284
- Q3 FY24: reported -$0.67 per share against an estimate of -$0.3978
- Q4 FY24: reported -$0.36 per share against an estimate of -$0.5712
- Q1 FY25: reported -$1.12 per share against an estimate of -$0.5304
- Q2 FY25: reported -$0.43 per share against an estimate of -$0.4182
ZIVO news
- Press releaseBusiness Wire
- Press releaseBusiness Wire
ZIVO Bioscience Provides Special Letter to Shareholders
- Press releaseBusiness Wire
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
- Press releaseBusiness Wire
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
- Press releaseBusiness Wire
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
- Press releaseBusiness Wire
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
- Press releaseBusiness Wire
ZIVO Bioscience to Present at The Microcap Conference 2025
- Press releaseBusiness Wire
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
Similar companies
Companies in the same industry as Zivo Bioscience
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.